{"id":"diphtheria-tetanus-pertussis-hib-vaccine","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site pain"},{"rate":"5-15%","effect":"Fever"},{"rate":"5-10%","effect":"Irritability"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The vaccine contains inactivated or attenuated pathogens, which are introduced to the body to trigger an immune response. This response produces antibodies that can recognize and neutralize the pathogens, providing immunity against future infections.","oneSentence":"This vaccine stimulates the body's immune response to produce antibodies against diphtheria, tetanus, pertussis, and Haemophilus influenzae type b.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:45:56.017Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of diphtheria, tetanus, pertussis, and Haemophilus influenzae type b infections in infants and children"}]},"trialDetails":[{"nctId":"NCT07160244","phase":"PHASE3","title":"BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-08-25","conditions":"Healthy","enrollment":6000},{"nctId":"NCT06397768","phase":"PHASE3","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-05-13","conditions":"RSV Immunization","enrollment":2226},{"nctId":"NCT06663436","phase":"PHASE2","title":"A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-11-13","conditions":"Diarrhoea","enrollment":200},{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT07354269","phase":"PHASE4","title":"Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2025-09-26","conditions":"Poliomyelitis","enrollment":180},{"nctId":"NCT06647407","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-05","conditions":"Meningococcal Immunization, Healthy Volunteers","enrollment":750},{"nctId":"NCT07320716","phase":"PHASE2","title":"Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-01-02","conditions":"Diarrhoea","enrollment":528},{"nctId":"NCT03891758","phase":"PHASE3","title":"Confirmatory Study of BK1310 in Healthy Infants","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2019-04-01","conditions":"Tetanus, Diphtheria, Pertussis","enrollment":267},{"nctId":"NCT03188692","phase":"PHASE3","title":"Safety and Efficacy of BK1310 Intramuscular Injection in Healthy Infants","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2017-06-23","conditions":"Immunization","enrollment":33},{"nctId":"NCT07203755","phase":"PHASE1","title":"Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine","status":"RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2025-12-19","conditions":"Diphtheria, Tetanus and Acellular Pertussis, Epidemic Meningitis, Haemophilus Influenzae Type B Infection","enrollment":260},{"nctId":"NCT05073003","phase":"PHASE1","title":"A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-06","conditions":"Diarrhoea","enrollment":551},{"nctId":"NCT04429295","phase":"PHASE3","title":"Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-06-28","conditions":"Pertussis Immunisation, Diphtheria Immunisation, Polio Immunisation","enrollment":460},{"nctId":"NCT05155579","phase":"PHASE1","title":"Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2022-05-14","conditions":"Malaria","enrollment":593},{"nctId":"NCT05091619","phase":"PHASE3","title":"A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed","status":"ACTIVE_NOT_RECRUITING","sponsor":"China National Biotec Group Company Limited","startDate":"2021-10-22","conditions":"Whooping Cough, Diphtheria, Tetanus","enrollment":2898},{"nctId":"NCT04398706","phase":"PHASE2","title":"Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-05-22","conditions":"Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation","enrollment":852},{"nctId":"NCT06879327","phase":"PHASE2","title":"Infant Malaria Vaccine Schedule Optimization","status":"RECRUITING","sponsor":"PATH","startDate":"2025-05-30","conditions":"Malaria Vaccines","enrollment":1200},{"nctId":"NCT06947499","phase":"PHASE2, PHASE3","title":"A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series","status":"RECRUITING","sponsor":"LG Chem","startDate":"2025-05-30","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":1186},{"nctId":"NCT05951725","phase":"PHASE3","title":"A Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed(DTcP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2023-08-11","conditions":"Diphtheria, Tetanus and Acellular Pertussis","enrollment":2520},{"nctId":"NCT03547271","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-12-14","conditions":"Meningococcal Infections","enrollment":1660},{"nctId":"NCT03566940","phase":"PHASE2","title":"A Study to Assess the Safety, Reactogenicity and Immunogenicity of a Trivalent Inactivated Poliovirus Vaccine (IPV) Based on Sabin Strains Compared to Conventional Salk IPV in a 6, 10 and 14 Weeks of Age Immunization Schedule","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2018-07-31","conditions":"Healthy","enrollment":302},{"nctId":"NCT06748612","phase":"PHASE4","title":"Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV)","status":"NOT_YET_RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2025-01-28","conditions":"Polio","enrollment":1190},{"nctId":"NCT02374450","phase":"","title":"A Surveillance Study of Diseases Specified as Adverse Events of Special Interest, of Other Adverse Events Leading to Hospitalisation or Death, and of Meningitis in Children in Africa Prior to Implementation of the RTS,S/AS01E Candidate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-10-05","conditions":"Malaria","enrollment":36366},{"nctId":"NCT04535037","phase":"PHASE4","title":"A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-05-26","conditions":"Diphtheria","enrollment":500},{"nctId":"NCT03691610","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-04","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":950},{"nctId":"NCT06344065","phase":"PHASE3","title":"Immunogenicity and Safety of Diphtheria, Tetanus, Pertussis (DTaP) Vaccine in 3-month-old Infants","status":"RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2023-12-21","conditions":"Healthy Volunteers","enrollment":1584},{"nctId":"NCT06333275","phase":"","title":"Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-11-14","conditions":"Vaccine Immunity in CAR-T Cell Therapy Recipients","enrollment":80},{"nctId":"NCT03530124","phase":"PHASE4","title":"Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines","status":"COMPLETED","sponsor":"Duke University","startDate":"2018-07-17","conditions":"Apnea, Apnea Neonatal, Prematurity","enrollment":223},{"nctId":"NCT06213506","phase":"PHASE2","title":"A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-01-15","conditions":"Salmonella Infections","enrollment":516},{"nctId":"NCT06184542","phase":"PHASE1","title":"Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine","status":"RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2023-12-23","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":460},{"nctId":"NCT03673462","phase":"PHASE3","title":"Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-09-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2797},{"nctId":"NCT03630705","phase":"PHASE3","title":"Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":525},{"nctId":"NCT05952596","phase":"PHASE1","title":"A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2023-07-17","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":42},{"nctId":"NCT05457946","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2023-04-01","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":1438},{"nctId":"NCT03620162","phase":"PHASE3","title":"A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-18","conditions":"Pneumococcal Infections","enrollment":900},{"nctId":"NCT04099303","phase":"PHASE1","title":"Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed .","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2020-04-28","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":400},{"nctId":"NCT04001322","phase":"NA","title":"Tunatar da ni. The Immunization Reminder and Information SMS System (IRISS)","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2019-06-15","conditions":"Low Immunization Uptake","enrollment":21},{"nctId":"NCT02447718","phase":"PHASE4","title":"Vaccinating Children After Chemotherapy","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2015-11-16","conditions":"Acute Lymphoblastic Leukemia","enrollment":156},{"nctId":"NCT01129362","phase":"","title":"Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-02-08","conditions":"Pertussis","enrollment":1195},{"nctId":"NCT00855855","phase":"","title":"Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-02","conditions":"Haemophilus Infections, Diphtheria, Tetanus","enrollment":20830},{"nctId":"NCT02274285","phase":"PHASE3","title":"DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2014-10","conditions":"Tetanus, Diphtheria, Pertussis","enrollment":424},{"nctId":"NCT03205371","phase":"PHASE3","title":"Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-11-07","conditions":"Meningitis, Meningococcal","enrollment":1183},{"nctId":"NCT02428491","phase":"PHASE3","title":"Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2015-04-20","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":354},{"nctId":"NCT01049035","phase":"PHASE2","title":"A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-12-16","conditions":"Meningitis, Meningococcal Infection","enrollment":580},{"nctId":"NCT01436396","phase":"PHASE3","title":"Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-09-07","conditions":"Dengue, Dengue Hemorrhagic Fever, Yellow Fever","enrollment":792},{"nctId":"NCT05095844","phase":"","title":"National Vaccine Adverse Event Reporting Survey and Etiology","status":"UNKNOWN","sponsor":"Neuroganics LLC","startDate":"2022-03-15","conditions":"COVID-19, Vaccine Adverse Reaction, Vaccine Reaction","enrollment":100000},{"nctId":"NCT02482636","phase":"PHASE2","title":"Baby Vaccine Study (Sched3)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-08","conditions":"Infectious Diseases","enrollment":189},{"nctId":"NCT01144663","phase":"PHASE3","title":"Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-01","conditions":"Infections, Meningococcal, Meningococcal Vaccines","enrollment":2095},{"nctId":"NCT03207750","phase":"PHASE3","title":"This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-09-14","conditions":"Rotavirus Infection, Rotavirus Vaccines","enrollment":1280},{"nctId":"NCT01453998","phase":"PHASE2","title":"Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-10-14","conditions":"Acellular Pertussis, Hepatitis B, Haemophilus Influenzae Type b","enrollment":657},{"nctId":"NCT03870061","phase":"NA","title":"Evaluation of an Infant Immunization Encouragement Program in Nigeria","status":"COMPLETED","sponsor":"GiveWell","startDate":"2018-07-01","conditions":"Tuberculosis, Diphtheria, Tetanus","enrollment":5187},{"nctId":"NCT00136604","phase":"PHASE3","title":"Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01-22","conditions":"Whole Cell Pertussis, Haemophilus Influenzae Type b, Hepatitis B","enrollment":617},{"nctId":"NCT00228917","phase":"PHASE3","title":"Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-06-16","conditions":"Whole Cell Pertussis, Tetanus, Hepatitis B","enrollment":798},{"nctId":"NCT01171989","phase":"PHASE2","title":"Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08-18","conditions":"Tetanus, Diphtheria, Haemophilus Influenzae Type b","enrollment":391},{"nctId":"NCT01577732","phase":"PHASE3","title":"Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-12-08","conditions":"Acellular Pertussis, Haemophilus Influenzae Type b, Tetanus","enrollment":321},{"nctId":"NCT00489554","phase":"PHASE3","title":"Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 12wks of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07-03","conditions":"Infections, Streptococcal, Streptococcus Pneumoniae Vaccines","enrollment":230},{"nctId":"NCT00463437","phase":"PHASE3","title":"Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04-25","conditions":"Hepatitis B, Acellular Pertussis, Tetanus","enrollment":1437},{"nctId":"NCT01353703","phase":"PHASE3","title":"Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-04-16","conditions":"Poliomyelitis, Tetanus, Acellular Pertussis","enrollment":224},{"nctId":"NCT01153841","phase":"PHASE3","title":"Primary Vaccination Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Vietnam","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02-17","conditions":"Infections, Streptococcal, Streptococcus Pneumoniae Vaccines","enrollment":300},{"nctId":"NCT02097472","phase":"PHASE1, PHASE2","title":"Dose-Finding Study of S.Pneumoniae Whole Cell Vaccine Adsorbed to Alum (PATH-wSP) in Healthy Kenyan Adults and Toddlers","status":"COMPLETED","sponsor":"PATH","startDate":"2014-04","conditions":"Pneumonia, Pneumococcal","enrollment":304},{"nctId":"NCT02858440","phase":"PHASE3","title":"A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-09-13","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":235},{"nctId":"NCT04073459","phase":"PHASE2","title":"Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2019-11","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":336},{"nctId":"NCT03208101","phase":"PHASE1","title":"A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults","status":"COMPLETED","sponsor":"LG Chem","startDate":"2017-07-03","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":42},{"nctId":"NCT03801161","phase":"NA","title":"Influence of Inflammation on Micronutrient Status Assessment","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2018-06-01","conditions":"Healthy Infants","enrollment":75},{"nctId":"NCT03000543","phase":"NA","title":"Novel Isotope Dilution Technique to Assess Vitamin A Status","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2016-11-01","conditions":"Healthy Infants, Infants With an Inflammatory Condition","enrollment":250},{"nctId":"NCT04056728","phase":"PHASE4","title":"A Phase IV Study to Assess the Safety of EupentaTM Inj","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2019-09-23","conditions":"Hepatitis B, Diphtheria, Haemophilus Influenzae Type B Infection","enrollment":3000},{"nctId":"NCT02712177","phase":"","title":"Bexsero™and Routine Infant Vaccines: Effect of Coadministration on the Safety of Immunization","status":"COMPLETED","sponsor":"CHU de Quebec-Universite Laval","startDate":"2008-08","conditions":"Meningococcal Infections","enrollment":4535},{"nctId":"NCT00466947","phase":"PHASE3","title":"COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06-28","conditions":"Infections, Streptococcal","enrollment":23802},{"nctId":"NCT02422264","phase":"PHASE4","title":"Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-01-22","conditions":"Acellular Pertussis, Tetanus, Poliomyelitis","enrollment":601},{"nctId":"NCT00652951","phase":"PHASE3","title":"Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV/Hib","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-04-01","conditions":"Infections, Streptococcal","enrollment":780},{"nctId":"NCT00370396","phase":"PHASE3","title":"Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09-25","conditions":"Infections, Streptococcal","enrollment":1200},{"nctId":"NCT01204658","phase":"PHASE2","title":"Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09-27","conditions":"Infections, Streptococcal","enrollment":576},{"nctId":"NCT01235949","phase":"PHASE4","title":"Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic Treatment","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-11-12","conditions":"Infections, Streptococcal","enrollment":850},{"nctId":"NCT03931239","phase":"NA","title":"The Transparent Safety Study of the 5 in 1 (DTwP-rHepB-Hib) Combination Vaccine Produced by the Indian Serine Institute in Children of Viet Nam Healthy From 6 to 12 Weeks of Age in a 3-dose Regimen, the Interval Between Doses is 4 Weeks","status":"COMPLETED","sponsor":"Vabiotech","startDate":"2018-03-01","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":222},{"nctId":"NCT01341639","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-05-26","conditions":"Bacterial Infections, Virus Diseases","enrollment":1250},{"nctId":"NCT01480258","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-11-23","conditions":"Bacterial Infections, Virus Diseases","enrollment":1315},{"nctId":"NCT01553279","phase":"PHASE3","title":"Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2012-03-30","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":284},{"nctId":"NCT01839188","phase":"PHASE3","title":"Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2013-05-01","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":385},{"nctId":"NCT01323647","phase":"PHASE3","title":"Immunogenicity and Safety of Booster Dose of PoliorixTM Vaccine in Previously Vaccinated Toddlers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-04-25","conditions":"Poliomyelitis","enrollment":957},{"nctId":"NCT00496015","phase":"PHASE3","title":"Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07-02","conditions":"Infections, Streptococcal","enrollment":750},{"nctId":"NCT00345358","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09-18","conditions":"Infections, Streptococcal","enrollment":600},{"nctId":"NCT00513409","phase":"PHASE2","title":"Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-08-22","conditions":"Infections, Streptococcal","enrollment":163},{"nctId":"NCT00390910","phase":"PHASE3","title":"Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-10-01","conditions":"Infections, Streptococcal","enrollment":286},{"nctId":"NCT01340937","phase":"PHASE3","title":"A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-05-10","conditions":"Bacterial Infections, Virus Diseases","enrollment":2808},{"nctId":"NCT01337167","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-04-19","conditions":"Bacterial Infections, Virus Diseases","enrollment":1473},{"nctId":"NCT01926015","phase":"PHASE4","title":"Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-09-19","conditions":"Rotavirus Disease","enrollment":192},{"nctId":"NCT02002156","phase":"PHASE4","title":"A Study of the Interaction Between BCG And MenC Immunisation: BAM","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2014-06-20","conditions":"BCG Infection, Reaction - Vaccine, Immune Response","enrollment":28},{"nctId":"NCT00310856","phase":"PHASE2","title":"Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2005-06","conditions":"Meningococcal Meningitis","enrollment":175},{"nctId":"NCT00614614","phase":"PHASE3","title":"Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-02-13","conditions":"Infections, Meningococcal","enrollment":1558},{"nctId":"NCT01119625","phase":"PHASE3","title":"Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Immunogenicity After Booster Dose","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-12","conditions":"Infections, Streptococcal","enrollment":238},{"nctId":"NCT02409095","phase":"PHASE4","title":"Study Comparing DTP-HB-Hib by Disposable-Syringe Jet Injector To Vaccination By Needle And Syringe In Infants","status":"TERMINATED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2015-01","conditions":"Immune Response to DTP-HB-Hib Vaccine","enrollment":211},{"nctId":"NCT00129116","phase":"PHASE2","title":"3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-03-01","conditions":"Haemophilus Influenzae Type b, Neisseria Meningitidis","enrollment":388},{"nctId":"NCT01248884","phase":"PHASE2","title":"Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-12-09","conditions":"Tetanus, Poliomyelitis, Hepatitis B","enrollment":721},{"nctId":"NCT00197236","phase":"PHASE3","title":"Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-11-11","conditions":"Hepatitis A","enrollment":468},{"nctId":"NCT00808444","phase":"PHASE3","title":"Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6-12wks of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-01-05","conditions":"Infections, Streptococcal","enrollment":466},{"nctId":"NCT00436007","phase":"PHASE2","title":"Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04-30","conditions":"Malaria","enrollment":511},{"nctId":"NCT02447432","phase":"PHASE3","title":"A Study to Compare the Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed 1-dose Synflorix™ (10Pn-PD-DiT) Vaccine When Co-administered With DTPw-combination Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-06-11","conditions":"Infections, Streptococcal","enrollment":320},{"nctId":"NCT01000974","phase":"PHASE3","title":"Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-06-18","conditions":"Haemophilus Influenzae Type b","enrollment":4003},{"nctId":"NCT00307034","phase":"PHASE3","title":"Safety & Immunogenicity Study of 10-Valent Pneumococcal Conjugate Vaccine When Administered as a 2-Dose Schedule","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01-01","conditions":"Infections, Streptococcal","enrollment":351},{"nctId":"NCT00533507","phase":"PHASE3","title":"Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 8 Weeks of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-09-18","conditions":"Infections, Rotavirus","enrollment":230},{"nctId":"NCT00196976","phase":"PHASE2","title":"Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-03-24","conditions":"Infections, Meningococcal","enrollment":461}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["diphtheria","tetanus","pertussis & Hib vaccine"],"phase":"phase_3","status":"active","brandName":"diphtheria, tetanus, pertussis & Hib vaccine","genericName":"diphtheria, tetanus, pertussis & Hib vaccine","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates the body's immune response to produce antibodies against diphtheria, tetanus, pertussis, and Haemophilus influenzae type b. Used for Prevention of diphtheria, tetanus, pertussis, and Haemophilus influenzae type b infections in infants and children.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}